Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COV155 PK and Food Effect Study in Healthy Subjects
NCT02561741Phase 1Completed
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Dec 2012
- Primary completion
- Dec 2012
01
Overview
Phase 1, randomised, open-label trial of MNK-155 in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoints: Area under the plasma concentration-time curve at 48 hours, Maximum observed plasma concentration at 48 hours and 1 more. Started Dec 2012; status: completed.
02
Drugs
MNK-155
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02561741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02561741.